Schwegel, N.; Toferer, C.; Zach, D.K.; Santner, V.; Höller, V.; Lugitsch, J.; Wallner, M.; Gollmer, J.; Aziz, F.; von Lewinski, D.;
et al. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. J. Clin. Med. 2024, 13, 5966.
https://doi.org/10.3390/jcm13195966
AMA Style
Schwegel N, Toferer C, Zach DK, Santner V, Höller V, Lugitsch J, Wallner M, Gollmer J, Aziz F, von Lewinski D,
et al. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. Journal of Clinical Medicine. 2024; 13(19):5966.
https://doi.org/10.3390/jcm13195966
Chicago/Turabian Style
Schwegel, Nora, Christina Toferer, David K. Zach, Viktoria Santner, Viktoria Höller, Jakob Lugitsch, Markus Wallner, Johannes Gollmer, Faisal Aziz, Dirk von Lewinski,
and et al. 2024. "Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study" Journal of Clinical Medicine 13, no. 19: 5966.
https://doi.org/10.3390/jcm13195966
APA Style
Schwegel, N., Toferer, C., Zach, D. K., Santner, V., Höller, V., Lugitsch, J., Wallner, M., Gollmer, J., Aziz, F., von Lewinski, D., Kolesnik, E., Ablasser, K., Zirlik, A., Sourij, H., & Verheyen, N.
(2024). Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. Journal of Clinical Medicine, 13(19), 5966.
https://doi.org/10.3390/jcm13195966
